Skip to main content
NCBI home page
Gut logoLink to Gut
. 1998 Sep;43(3):422–427. doi: 10.1136/gut.43.3.422

Prognostic factors in patients with endocrine tumours of the duodenopancreatic area

I Madeira 1, B Terris 1, M Voss 1, A Denys 1, A Sauvanet 1, J Flejou 1, V Vilgrain 1, J Belghiti 1, P Bernades 1, P Ruszniewski 1
PMCID: PMC1727238  PMID: 9863490

Abstract

Background—The development of endocrine tumours of the duodenopancreatic area (ETDP) is thought to be slow, but their natural history is not well known. The aim of this study was to determine the factors that influence survival of patients with ETDP. 
Patients/Methods—Eighty two patients with ETDP (44 non-functioning tumours, 23 gastrinomas, seven calcitonin-secreting tumours, four glucagonomas, three insulinomas, one somatostatinoma) followed from October 1991 to June 1997 were included in the study. The following factors were investigated: primary tumour size, hormonal clinical syndrome, liver metastases, lymph node metastases, extranodular/extrahepatic metastases, progression of liver metastases, local invasion, complete resection of the primary tumour, and degree of tumoral differentiation. The prognostic significance of these factors was investigated by uni- and multi-variate analysis. 
Results—Twenty eight patients (34%) died within a median of 17 months (range 1-110) from diagnosis. Liver metastases (p =0.001), lymph node metastases (p = 0.001), progression of liver metastases (p<0.00001), lack of complete resection of the primary tumour (p = 0.001), extranodular/extrahepatic metastases (p =0.001), local invasion (p = 0.001), primary tumour size ⩾3 cm (p = 0.001), non-functioning tumours (p = 0.02), and poor tumoral differentiation (p = 0.006) were associated with an unfavourable outcome by univariate analysis. Multivariate analysis identified only liver metastases (risk ratio (RR) = 8.3; p<0.0001), poor tumoral cell differentiation (RR = 8.1; p = 0.0001), and lack of complete resection of the primary tumour (RR = 4.8; p = 0.0007) as independent risk factors. Five year survival rates were 40and 100% in patients with and without liver metastases, 85 and 42% in patients with and without complete resection of primary tumour, and 17 and 71% in patients with poor and good tumour cell differentiation respectively. 
Conclusion—Liver metastases are a major prognostic factor in patients with ETDP. Progression of liver metastases is also an important factor which must be taken into account when deciding on the therapeutic approach. The only other independent prognostic factors are tumoral cell differentiation and complete resection of the primary tumour. 



Keywords: prognostic factors; survival; endocrine tumours; gastrinoma; cell differentiation; liver metastases

Full Text

The Full Text of this article is available as a PDF (128.7 KB).

Figure 1 .

Figure 1

Open in a new tab

Overall survival after diagnosis among 82 patients with endocrine tumours of the duodenopancreatic area, according to the presence of liver metastases (log rank test; p = 0.0001). The asterisks indicate the number of patients at risk. 


Figure 2 .

Figure 2

Open in a new tab

Overall survival after diagnosis among 82 patients with endocrine tumours of the duodenopancreatic area, according to complete resection of the primary tumour (log rank test; p = 0.0001). The asterisks indicate the number of patients at risk. 


Figure 3 .

Figure 3

Open in a new tab

Overall survival after diagnosis among 73 patients with endocrine tumours of the duodenopancreatic area according to the cell differentiation of the primary tumour (log rank test; p = 0.0001). The asterisks indicate the number of patients at risk. 


Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Carty S. E., Jensen R. T., Norton J. A. Prospective study of aggressive resection of metastatic pancreatic endocrine tumors. Surgery. 1992 Dec;112(6):1024–1032. [PubMed] [Google Scholar]
  2. Danforth D. N., Jr, Gorden P., Brennan M. F. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. Surgery. 1984 Dec;96(6):1027–1037. [PubMed] [Google Scholar]
  3. Eriksson B., Oberg K., Skogseid B. Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol. 1989;28(3):373–377. doi: 10.3109/02841868909111209. [DOI] [PubMed] [Google Scholar]
  4. Friesen S. R. Tumors of the endocrine pancreas. N Engl J Med. 1982 Mar 11;306(10):580–590. doi: 10.1056/NEJM198203113061005. [DOI] [PubMed] [Google Scholar]
  5. Kenny B. D., Sloan J. M., Hamilton P. W., Watt P. C., Johnston C. F., Buchanan K. D. The role of morphometry in predicting prognosis in pancreatic islet cell tumors. Cancer. 1989 Jul 15;64(2):460–465. doi: 10.1002/1097-0142(19890715)64:2<460::aid-cncr2820640220>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  6. McEntee G. P., Nagorney D. M., Kvols L. K., Moertel C. G., Grant C. S. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery. 1990 Dec;108(6):1091–1096. [PubMed] [Google Scholar]
  7. Metz D. C., Kuchnio M., Fraker D. L., Venzon D. J., Jaffe G., Jensen R. T., Stetler-Stevenson M. Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. Gastroenterology. 1993 Sep;105(3):799–813. doi: 10.1016/0016-5085(93)90898-m. [DOI] [PubMed] [Google Scholar]
  8. Mignon M., Bonfils S. Diagnosis and treatment of Zollinger-Ellison syndrome. Baillieres Clin Gastroenterol. 1988 Jul;2(3):677–698. doi: 10.1016/s0950-3528(88)80013-7. [DOI] [PubMed] [Google Scholar]
  9. Mignon M., Ruszniewski P., Haffar S., Rigaud D., Rene E., Bonfils S. Current approach to the management of tumoral process in patients with gastrinoma. World J Surg. 1986 Aug;10(4):703–710. doi: 10.1007/BF01655562. [DOI] [PubMed] [Google Scholar]
  10. Moertel C. G., Kvols L. K., O'Connell M. J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991 Jul 15;68(2):227–232. doi: 10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  11. Pelosi G., Bresaola E., Bogina G., Pasini F., Rodella S., Castelli P., Iacono C., Serio G., Zamboni G. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996 Nov;27(11):1124–1134. doi: 10.1016/s0046-8177(96)90303-2. [DOI] [PubMed] [Google Scholar]
  12. Prinz R. A., Badrinath K., Banerji M., Sparagana M., Dorsch T. R., Lawrence A. M. Operative and chemotherapeutic management of malignant glucagon-producing tumors. Surgery. 1981 Oct;90(4):713–719. [PubMed] [Google Scholar]
  13. Rüschoff J., Willemer S., Brunzel M., Trautmann M. E., Frank M., Arnold R., Klöppel G. Nucleolar organizer regions and glycoprotein-hormone alpha-chain reaction as markers of malignancy in endocrine tumours of the pancreas. Histopathology. 1993 Jan;22(1):51–57. doi: 10.1111/j.1365-2559.1993.tb00069.x. [DOI] [PubMed] [Google Scholar]
  14. Stabile B. E., Passaro E., Jr Benign and malignant gastrinoma. Am J Surg. 1985 Jan;149(1):144–150. doi: 10.1016/s0002-9610(85)80024-6. [DOI] [PubMed] [Google Scholar]
  15. Thompson G. B., van Heerden J. A., Martin J. K., Jr, Schutt A. J., Ilstrup D. M., Carney J. A. Carcinoid tumors of the gastrointestinal tract: presentation, management, and prognosis. Surgery. 1985 Dec;98(6):1054–1063. [PubMed] [Google Scholar]
  16. Travis W. D., Linnoila R. I., Tsokos M. G., Hitchcock C. L., Cutler G. B., Jr, Nieman L., Chrousos G., Pass H., Doppman J. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991 Jun;15(6):529–553. doi: 10.1097/00000478-199106000-00003. [DOI] [PubMed] [Google Scholar]
  17. Viale G., Doglioni C., Gambacorta M., Zamboni G., Coggi G., Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors. An immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992 Nov 1;70(9):2268–2277. doi: 10.1002/1097-0142(19921101)70:9<2268::aid-cncr2820700910>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  18. Weber H. C., Venzon D. J., Lin J. T., Fishbein V. A., Orbuch M., Strader D. B., Gibril F., Metz D. C., Fraker D. L., Norton J. A. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology. 1995 Jun;108(6):1637–1649. doi: 10.1016/0016-5085(95)90124-8. [DOI] [PubMed] [Google Scholar]
  19. Zollinger R. M. Gastrinoma: factors influencing prognosis. Surgery. 1985 Jan;97(1):49–54. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES